ATE480259T1 - Intranasale verabreichung von glucose- regulierenden peptiden - Google Patents

Intranasale verabreichung von glucose- regulierenden peptiden

Info

Publication number: ATE480259T1
Authority: AT; Austria
Prior art keywords: glucose; intranasal administration; regulating peptides; amylin; mucosal delivery
Prior art date: 2003-12-26

Application number

AT04815393T

Other languages

English (en)

Inventor

Steven Quay

Henry Costantino

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-26

Filing date

2004-12-17

Publication date

2010-09-15

2004-12-17 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE480259T1 publication Critical patent/ATE480259T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 2
102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 2
102100040918 Pro-glucagon Human genes 0.000 abstract 2
108010011459 Exenatide Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960001519 exenatide Drugs 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
108010029667 pramlintide Proteins 0.000 abstract 1
229960003611 pramlintide Drugs 0.000 abstract 1
NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Otolaryngology (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pulmonology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Inorganic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT04815393T 2003-12-26 2004-12-17 Intranasale verabreichung von glucose- regulierenden peptiden ATE480259T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53233703P	2003-12-26	2003-12-26
PCT/US2004/043312 WO2005065714A1 (en)	2003-12-26	2004-12-17	Intranasal administration of glucose-regulating peptides

Publications (1)

Publication Number	Publication Date
ATE480259T1 true ATE480259T1 (de)	2010-09-15

Family

ID=34748791

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04815393T ATE480259T1 (de)	2003-12-26	2004-12-17	Intranasale verabreichung von glucose- regulierenden peptiden

Country Status (16)

Country	Link
US (1)	US20050143303A1 (de)
EP (1)	EP1696960B1 (de)
JP (1)	JP2007518722A (de)
KR (1)	KR20060134036A (de)
CN (1)	CN1933855A (de)
AT (1)	ATE480259T1 (de)
AU (1)	AU2004312043B2 (de)
CA (1)	CA2551530A1 (de)
DE (1)	DE602004029086D1 (de)
ES (1)	ES2350487T3 (de)
IL (1)	IL176541A0 (de)
MX (1)	MXPA06007317A (de)
NO (1)	NO20063436L (de)
NZ (1)	NZ548695A (de)
WO (1)	WO2005065714A1 (de)
ZA (1)	ZA200606153B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070032410A1 (en) *	2000-01-11	2007-02-08	Atossa Healthcare, Inc.	Compositions and methods for the treatment of psychiatric disorders
US7244703B2 (en) *	2001-06-22	2007-07-17	Bentley Pharmaceuticals, Inc.	Pharmaceutical compositions and methods for peptide treatment
JP2004535432A (ja) *	2001-06-22	2004-11-25	ベントレーファーマシューティカルズインコーポレイテッド	医薬組成物
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
DE60335608D1 (de) *	2002-02-27	2011-02-17	Pharmain Corp	Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
EP1631308B1 (de) *	2003-05-30	2013-07-31	Amylin Pharmaceuticals, LLC	Neue verfahren und zusammensetzungen für die verbesserte transmukosale abgabe von peptiden und proteinen
WO2007065156A2 (en) *	2005-12-02	2007-06-07	Nastech Pharmaceutical Company Inc.	Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
US20080318837A1 (en) *	2003-12-26	2008-12-25	Nastech Pharmaceutical Company Inc.	Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060210614A1 (en) *	2003-12-26	2006-09-21	Nastech Pharmaceutical Company Inc.	Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20060074025A1 (en) *	2003-12-26	2006-04-06	Nastech Pharmaceutical Company Inc.	Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
WO2005112977A2 (en) *	2004-04-23	2005-12-01	Pharmain, Ltd.	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20090069226A1 (en) *	2004-05-28	2009-03-12	Amylin Pharmaceuticals, Inc.	Transmucosal delivery of peptides and proteins
US8062652B2 (en)	2004-06-17	2011-11-22	Endo Pharmaceuticals Solutions Inc.	Compositions and methods for treating precocious puberty
US8394765B2 (en) *	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
CN101094689B (zh) *	2004-11-01	2013-06-12	安米林药品有限责任公司	治疗肥胖以及肥胖相关疾病和病症的方法
CN101193626A (zh) *	2005-03-11	2008-06-04	益德威士医药股份有限公司	奥曲肽的受控释放制剂
US7759312B2 (en) *	2005-03-11	2010-07-20	Endo Pharmaceuticals Solutions Inc.	Delivery of dry formulations of octreotide
WO2007029238A2 (en) *	2005-09-06	2007-03-15	Oramed Pharmaceuticals, Inc.	Methods and compositions for oral administration of proteins
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
WO2007061434A2 (en) *	2005-11-10	2007-05-31	Nastech Pharmaceutical Company Inc.	A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
US20080318861A1 (en) *	2005-12-08	2008-12-25	Nastech Pharmaceutical Company Inc.	Mucosal Delivery of Stabilized Formulations of Exendin
EP2364735A3 (de)	2005-12-16	2012-04-11	Nektar Therapeutics	Verzweigte PEG-Kon jugate von GLP-1
KR101529318B1 (ko)	2005-12-19	2015-06-16	파마인 코포레이션	치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
WO2007111933A2 (en) *	2006-03-22	2007-10-04	Intranasal Therapeutics , Inc.	Pharmaceutical compositions comprising a hypoglycemic agent and methods of using same
WO2007146448A1 (en) *	2006-06-07	2007-12-21	Nastech Pharmaceutical Company Inc.	Pharmaceutical formulations of glp-1 derivatives
JP2010043001A (ja) *	2006-11-09	2010-02-25	Sanwa Kagaku Kenkyusho Co Ltd	Ｇｌｐ−１誘導体とその用途
CA2685397C (en) *	2007-04-27	2016-07-26	Endo Pharmaceuticals Solutions Inc.	Implant device release agents and methods of using same
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
JP2010539002A (ja) *	2007-09-11	2010-12-16	モンドバイオテックラボラトリーズアクチエンゲゼルシャフト	ウロジラチンの治療剤としての使用
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
NZ588603A (en) *	2008-03-26	2012-03-30	Oramed Ltd	Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
CN101548961B (zh) *	2008-04-03	2011-05-04	单宝华	一种治疗糖尿病及肥胖症的口服胶囊制剂
US20110046053A1 (en)	2008-05-05	2011-02-24	Oramed Ltd.	Methods and compositions for oral administration of exenatide
CA2729139C (en)	2008-06-25	2016-07-26	Endo Pharmaceuticals Solutions Inc.	Octreotide implant having a release agent
EP2303226B1 (de) *	2008-06-25	2016-03-23	Endo Pharmaceuticals Solutions Inc.	Verlängerte freisetzung von exenatid und anderen polypeptiden
ES2610356T3 (es)	2009-02-03	2017-04-27	Amunix Operating Inc.	Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US20100203014A1 (en) *	2009-02-04	2010-08-12	Aegis Therapeutics Llc	Zwitterionic buffered acidic peptide and protein formulations
CN101822822A (zh) *	2009-03-04	2010-09-08	北京德众万全药物技术开发有限公司	一种普兰林肽的药物组合物及其制备方法
WO2010144508A1 (en) *	2009-06-08	2010-12-16	Amunix Operating Inc.	Glucose-regulating polypeptides and methods of making and using same
CN102309453A (zh) *	2011-09-27	2012-01-11	四川大学	醋酸艾塞那肽多囊脂质体及其制备方法
EP3260131A1 (de)	2012-01-03	2017-12-27	Oramed Ltd.	Kapseln enthaltend ölige flüssige zusammensetzungen von kombinierten therapeutischen wirkstoffen zur behandlung von diabetes
CN113769074A (zh)	2012-02-01	2021-12-10	奥拉姆德有限公司	含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
WO2014106846A2 (en)	2013-01-03	2014-07-10	Oramed Ltd.	Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
BR102013017626A2 (pt) *	2013-06-14	2015-02-10	Univ Rio De Janeiro	Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
CN103405753B (zh) *	2013-08-13	2016-05-11	上海仁会生物制药股份有限公司	稳定的促胰岛素分泌肽水针药物组合物
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
EP3080154B1 (de)	2013-12-13	2018-02-07	Sanofi	Duale glp-1/gip-rezeptoragonisten
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
CN103948544B (zh) *	2014-04-08	2016-02-17	河南农业大学	重组Exendin-4鼻腔喷雾剂及其制备方法
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3117831A1 (de) *	2015-07-16	2017-01-18	Nuritas Limited	Peptide zur verwendung bei der förderung des glucosetransports in skelettmuskeln
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
CN108079280B (zh) *	2017-12-30	2021-06-04	陕西慧康生物科技有限责任公司	治疗ⅱ型糖尿病的艾塞那肽滴鼻剂
CN109136176A (zh) *	2018-07-03	2019-01-04	华东师范大学	一种小鼠冻存精子复苏液复合物及其配制方法和应用
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤
CN117979954A (zh) *	2021-09-22	2024-05-03	辉凌有限公司	促肾上腺皮质激素肽组合物及使用方法
TW202535912A (zh) *	2024-01-12	2025-09-16	大陸商杭州中美華東製藥有限公司	長效glp-1/gip雙激動劑的鼻腔遞送藥物組合物
CN118001259B (zh) *	2024-02-06	2024-09-20	上海万良诚科医药科技有限公司	曲普瑞林口颊膜及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US3972995A (en) *	1975-04-14	1976-08-03	American Home Products Corporation	Dosage form
US4235871A (en) *	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
JPS5562012A (en) *	1978-11-06	1980-05-10	Teijin Ltd	Slow-releasing preparation
GB2042888B (en) *	1979-03-05	1983-09-28	Teijin Ltd	Preparation for administration to the mucosa of the oral or nasal cavity
US4259314A (en) *	1979-12-10	1981-03-31	Hans Lowey	Method and composition for the preparation of controlled long-acting pharmaceuticals
US4675189A (en) *	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
JPS57110254A (en) *	1980-12-29	1982-07-09	Teijin Ltd	Coating agent of injured membrane part of oral cavity
JPS58500845A (ja) *	1981-06-04	1983-05-26	デラウェア・ケミカルス・コーポレーション	ポンプ
US4501728A (en) *	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
US4680323A (en) *	1983-12-01	1987-07-14	Hans Lowey	Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4573996A (en) *	1984-01-03	1986-03-04	Jonergin, Inc.	Device for the administration of an active agent to the skin or mucosa
US4740365A (en) *	1984-04-09	1988-04-26	Toyo Boseki Kabushiki Kaisha	Sustained-release preparation applicable to mucous membrane in oral cavity
CA1256638A (en) *	1984-07-06	1989-06-27	Motoaki Tanaka	Polymer and its production
JP2551756B2 (ja) *	1985-05-07	1996-11-06	武田薬品工業株式会社	ポリオキシカルボン酸エステルおよびその製造法
JPH0729915B2 (ja) *	1986-02-01	1995-04-05	帝國製薬株式会社	シ−ト状口腔内貼付剤
JP2583257B2 (ja)	1986-05-05	1997-02-19	ザ・ジェネラル・ホスピタル・コーポレーション	インシュリン向性ホルモン
USRE33093E (en) *	1986-06-16	1989-10-17	Johnson & Johnson Consumer Products, Inc.	Bioadhesive extruded film for intra-oral drug delivery and process
US4837028A (en) *	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US4855142A (en) *	1987-02-27	1989-08-08	Ciba-Geigy Corporation	Pharmaceutical plaster
PT88490B (pt) *	1987-09-14	1992-11-30	Novo Nordisk As	Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
US4948580A (en) *	1988-12-08	1990-08-14	E. R. Squibb & Sons, Inc.	Muco-bioadhesive composition
NL9001681A (nl) *	1990-07-24	1992-02-17	Rijksuniversiteit	Transmucosale geneesmiddelpreparaten en transmucosale toediening.
DK36492D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
US6190894B1 (en) *	1993-03-19	2001-02-20	The Regents Of The University Of California	Method and compositions for disrupting the epithelial barrier function
US5681811A (en) *	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JPH0859503A (ja) *	1994-08-26	1996-03-05	Teijin Ltd	ペプチド・蛋白質性薬物の経口、経粘膜投与用リポソーム製剤
US6004583A (en) *	1995-03-22	1999-12-21	Orex Pharmaceutical Development Corp.	Protein-containing polymer composition for oral administration
JPH11292787A (ja) *	1995-08-15	1999-10-26	Asahi Chem Ind Co Ltd	生理活性ペプチドを含有する経粘膜投与製剤
WO1997046584A1 (de) *	1996-06-05	1997-12-11	Boehringer Mannheim Gmbh	Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US7312196B2 (en) *	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US5908825A (en) *	1997-01-09	1999-06-01	University Of Maryland At Baltimore	Dosage composition for nasal delivery and method of use of the same
US6221378B1 (en) *	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US20030087820A1 (en) *	1999-01-14	2003-05-08	Young Andrew A.	Novel exendin agonist formulations and methods of administration thereof
US6506724B1 (en) *	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US20010012829A1 (en) *	2000-01-11	2001-08-09	Keith Anderson	Transepithelial delivery GLP-1 derivatives
US6540983B1 (en) *	2000-01-25	2003-04-01	Aeropharm Technology Incorporated	Medical aerosol formulation
US20050222036A1 (en) *	2000-08-24	2005-10-06	Thomas Jefferson University	Peptide compositions with effects on blood glucose
WO2003002136A2 (en) *	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
ATE469645T1 (de) *	2002-10-23	2010-06-15	Bristol Myers Squibb Co	Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US20040258663A1 (en) *	2003-05-08	2004-12-23	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of interferon alpha
EP1631308B1 (de) *	2003-05-30	2013-07-31	Amylin Pharmaceuticals, LLC	Neue verfahren und zusammensetzungen für die verbesserte transmukosale abgabe von peptiden und proteinen
US20060210614A1 (en) *	2003-12-26	2006-09-21	Nastech Pharmaceutical Company Inc.	Method of treatment of a metabolic disease using intranasal administration of exendin peptide

2004
- 2004-11-18 US US10/991,597 patent/US20050143303A1/en not_active Abandoned
- 2004-12-17 JP JP2006547366A patent/JP2007518722A/ja active Pending
- 2004-12-17 AU AU2004312043A patent/AU2004312043B2/en not_active Ceased
- 2004-12-17 EP EP04815393A patent/EP1696960B1/de not_active Expired - Lifetime
- 2004-12-17 AT AT04815393T patent/ATE480259T1/de not_active IP Right Cessation
- 2004-12-17 NZ NZ548695A patent/NZ548695A/en unknown
- 2004-12-17 DE DE602004029086T patent/DE602004029086D1/de not_active Expired - Lifetime
- 2004-12-17 WO PCT/US2004/043312 patent/WO2005065714A1/en not_active Ceased
- 2004-12-17 ES ES04815393T patent/ES2350487T3/es not_active Expired - Lifetime
- 2004-12-17 CA CA002551530A patent/CA2551530A1/en not_active Abandoned
- 2004-12-17 CN CNA2004800421626A patent/CN1933855A/zh active Pending
- 2004-12-17 MX MXPA06007317A patent/MXPA06007317A/es active IP Right Grant
- 2004-12-17 KR KR1020067015029A patent/KR20060134036A/ko not_active Ceased
2006
- 2006-06-25 IL IL176541A patent/IL176541A0/en unknown
- 2006-07-25 ZA ZA200606153A patent/ZA200606153B/xx unknown
- 2006-07-25 NO NO20063436A patent/NO20063436L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2004312043A1 (en)	2005-07-21
JP2007518722A (ja)	2007-07-12
US20050143303A1 (en)	2005-06-30
EP1696960A1 (de)	2006-09-06
ZA200606153B (en)	2007-12-27
CA2551530A1 (en)	2005-07-21
WO2005065714A1 (en)	2005-07-21
NZ548695A (en)	2008-04-30
CN1933855A (zh)	2007-03-21
DE602004029086D1 (de)	2010-10-21
AU2004312043B2 (en)	2008-07-31
IL176541A0 (en)	2006-10-05
NO20063436L (no)	2006-08-25
EP1696960B1 (de)	2010-09-08
ES2350487T3 (es)	2011-01-24
MXPA06007317A (es)	2007-01-26
KR20060134036A (ko)	2006-12-27

Legal Events

Date	Code	Title	Description
2011-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE480259T1 (de)	2010-09-15	Intranasale verabreichung von glucose- regulierenden peptiden
AR022368A1 (es)	2002-09-04	Procedimiento para administrar peptidos insulinotropicos
ATE251642T1 (de)	2003-10-15	Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides
SA521421080B1 (ar)	2024-11-04	مركبات مساعدة مشتركة البولي ببتيد المفرزة للإنسولين المعتمدة على الجلوكوز/ الببتيد-1 الشبيه بجلوكاجون
WO2003011892A3 (en)	2004-02-26	Glp-1 exendin-4 peptide analogs and uses thereof
WO2005115441A3 (en)	2006-03-16	Compositions and methods for enhanced mucosal delivery of parathyroid hormone
PL2070946T3 (pl)	2013-09-30	Wynalazek dotyczący GLP-1 i eksendyny
NO20071018L (no)	2007-04-11	Kombinasjonsbehandling ved a anvende fusjonsproteiner omfattende GLP-1
MX2022009149A (es)	2022-12-15	Compuestos coagonistas de gip/glp1.
WO2007028394A3 (en)	2007-09-20	Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
WO2003033671A3 (en)	2005-12-29	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2004509079A5 (de)	2005-08-18
DK1294757T3 (da)	2007-03-19	Glucagonlignende peptid 1-analoger
ATE466028T1 (de)	2010-05-15	N-terminal veränderte glp-1 abkömmlinge
UA97953C2 (uk)	2012-04-10	Стабілізовані поліпептиди інсуліноподібного фактора росту
MXPA01009805A (es)	2004-07-30	Peptido.
NZ621196A (en)	2015-08-28	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NO940436D0 (no)	1994-02-09	Forlenget avgivelse av peptider
WO2004094461A3 (en)	2005-09-15	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
NO20082958L (no)	2008-08-26	Humane glukagon-lignende-peptid-1 modulatorer og anvendelse derav for behandling av diabetes og beslektede tilstander
IL146868A0 (en)	2002-08-14	A pharmaceutical composition containing an igf-i/igfbp-3 complex
Youn et al.	2008	Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation
DK1515745T3 (da)	2009-07-13	Anvendelse af forbindelser med biologiskaktivitet af vasoaktivt intestinalt peptid til behandlingen af sarkoidose
EP2210900A3 (de)	2010-08-11	GlLP-1-Analoga
TW200509960A (en)	2005-03-16	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity